N,N,N',N'-Ethylenediaminetetrakis

CAS : 1429-50-1

Ref. 3D-FE75418

Informations sur le produit

• Nom: N,N,N',N'-Ethylenediaminetetrakis
• Synonymes: ([[2-(Bis-phosphonomethyl-amino)-ethyl]-phosphonomethyl-amino]-methyl)-phosphonic acid, 1,2-Ethanediylbis[nitrilobis(methylene)]tetrakisphosphonic acid, Acide [ethane-1,2-diylbis[nitrilobis(methylene)]]tetrakisphosphonique, Acido [Etano-1,2-Diilbis[Nitrilobis(Metilen)]]Tetrakisfosfonico, Aethylendinitrilo-Tetrakis-(Methylenphosphonsaeure), Briquest 422-25S, Chelating agent 540, Chelest PH 540, Cublen 3115, Cublen E 950, Dequest 2040, Dequest 2041, EDPA (chelating agent), Editempa, Edpa, Edtf, Edtmp, Edtmpa, Edtmps, Edtpa, Edtph, Ethylenedi(nitrilodimethylene)tetraphosphonic acid, Ethylenediamine tetra (methylenephosphonic acid), Ethylenediamine-N,N,N',N'-tetra(methylphosphonic acid), Ethylenediamine-N,N,N',N'-tetrakis(methylenephosphonic acid), Ethylenediaminetetra(methylenephosphonic acid), Ethylenediaminetetrakis(methylenephosphonic acid), Ethylenediaminetetrakis(methylphosphonic acid), Ethylenediaminetetramethylenephosphonate, Ethylenediaminotetra(methylenephosphonic acid), N,N,N',N'-Tetrakis (phosphonomethyl) ethylenediamine, P,P′,P′′,P′′′-[1,2-Ethanediylbis[nitrilobis(methylene)]]tetrakis[phosphonic acid], Ph 540, Phosphonic acid, P,P',P'',P'''-[1,2-ethanediylbis[nitrilobis(methylene)]]tetrakis-, Phosphonic acid, [ethylenebis(nitrilodimethylene)]tetra-, Wayplex 45K, [2-[Bis(phosphonomethyl)amino]ethyl-(phosphonomethyl)amino]methylphosphonic acid, [Ethan-1,2-diylbis[nitrilobis(methylen)]]tetrakisphosphonsaure, [Ethane-1,2-Diylbis[Nitrilobis(Methylene)]]Tetrakisphosphonic Acid, [Ethylenebis(nitrilodimethylene)]tetraphosphonic acid
• CAS: 1429-50-1

Description

N,N,N',N'-Ethylenediaminetetrakis (EDTA) is a chelating agent that has been shown to be effective in the treatment of parathyroid tumours. It is administered intravenously and has been shown to bind to phosphonic acid in the body and prevent its accumulation in the bones. This prevents the development of osteoblastic lesions, which may lead to bone pain and fractures. EDTA has also been shown to have relatively low toxicity with no detectable side effects on animals. The biodistribution and uptake of this drug was monitored using scintigraphy following intravenous injection in rats. EDTA was found to be taken up by all tissues equally and distributed evenly throughout the body.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 436.12 g/mol
• Formule: C₆H₂₀N₂O₁₂P₄
• InChI: InChI=1S/C6H20N2O12P4/c9-21(10,11)3-7(4-22(12,13)14)1-2-8(5-23(15,16)17)6-24(18,19)20/h1-6H2,(H2,9,10,11)(H2,12,13,14)(H2,15,16,17)(H2,18,19,20)
• Code InChI: InChIKey=NFDRPXJGHKJRLJ-UHFFFAOYSA-N
• SMILES: O=P(O)(O)CN(CCN(CP(=O)(O)O)CP(=O)(O)O)CP(=O)(O)O